Niagen Bioscience, Inc. — Director's Dealing 2008

Jun 26, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ChromaDex Corp. (CDYE(4))
CIK: 0001386570
Period of Report: 2008-06-25

Reporting Person: Varvaro Thomas C (Director, CFO and Secretary)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1	2014-01-19	Common Stock (240000)		Direct
Stock Option (right to buy)	$1	2014-01-19	Common Stock (10000)		Direct
Stock Option (right to buy)	$1.5	2016-12-01	Common Stock (250000)		Direct
Stock Option (right to buy)	$1.5	2018-04-21	Common Stock (100000)		Direct

Footnotes

F1: The stock options are exercisable any time, at the holder's election.

F2: 50,000 options are exercisable anytime, at the holder's election. An additional 50,000 options become exercisable every year on December 1.

F3: 25,000 options become exercisable on April 21, 2009 and 1,562 options become exercisable monthly thereafter, except that 1,563 options become exercisable every fourth month.